Global Daptomycin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

According to our (Global Info Research) latest study, the global Daptomycin market size was valued at US$ 68.95 million in 2025 and is forecast to a readjusted size of US$ 114 million by 2032 with a CAGR of 7.2% during review period.
In 2025, global Daptomycin capacity 5 Tons, sales reached approximately 4.5 Tons, with an average market price of around 14,890 USD/Kg, industrial gross margin 28%.
Daptomycin is a cyclic lipopeptide antibacterial positioned in the high-value, low-tonnage segment of the anti-infective API industry, where process control and regulatory continuity matter materially more than nominal manufacturing scale. The molecule has the formula C₇₂H₁₀₁N₁₇O₂₆ and a molecular weight of approximately 1,620.7 Da; its antibacterial activity is driven by calcium-dependent insertion into Gram-positive bacterial membranes, rapid membrane depolarization, and subsequent arrest of DNA, RNA and protein synthesis. The relevant industrial market is pharmaceutical-grade API or drug substance rather than finished 350 mg or 500 mg injectable vials, laboratory reagents, analytical standards or fermentation intermediates. Commercial API programs are typically positioned in the high-98% to ≥99% HPLC purity range, but pharmaceutical suitability is governed by a broader specification covering individual and total related substances, residual solvents, water, microbiological attributes and stability. Storage is process- and registration-specific: validated commercial supply chains may use refrigerated conditions of 2–8°C or frozen storage around −20°C, while registered products can carry shelf lives of approximately three years. These requirements make stability data, cold-chain control and manufacturing-change discipline integral to commercial qualification rather than secondary logistics considerations.
The manufacturing platform is built around controlled microbial fermentation followed by a purification train that is substantially more demanding than conventional small-molecule API synthesis. Industrial production uses Streptomyces roseosporus fermentation with controlled fatty-acid precursor feeding, followed by broth clarification, adsorption, ion-exchange chromatography, hydrophobic-interaction or reversed-phase chromatography, membrane concentration and final crystallization or lyophilization. Cost competitiveness is determined by strain productivity, precursor-feed control, impurity formation, chromatographic selectivity, resin productivity and downstream recovery rather than fermenter volume alone. Structurally related lipopeptide congeners are difficult to separate, and incremental purity improvement can require disproportionate resin, solvent and product-loss penalties. As a result, process development is moving upstream: preventing unwanted analogues during fermentation is economically preferable to removing them through additional chromatography. The supply chain therefore extends beyond conventional fermentation nutrients to specialized resins, membrane systems, high-purity solvents, analytical instrumentation and validated clean utilities. Downstream customers are sterile-injectable manufacturers, and supplier onboarding commonly involves analytical comparability, stability packages, quality-system audits, regulatory-file access, validation batches and formal change-control arrangements.
Demand is anchored in serious Gram-positive infections rather than broad outpatient antibiotic use, which gives the product a resilient but clinically bounded commercial profile. Approved applications include complicated skin and skin-structure infections and Staphylococcus aureus bloodstream infections, including right-sided infective endocarditis. Typical adult regimens include 4 mg/kg every 24 hours for cSSSI and 6 mg/kg every 24 hours for S. aureus bacteremia, with extended dosing intervals in severe renal impairment. Daptomycin is not indicated for pneumonia, which materially limits the addressable clinical setting relative to several broad-spectrum agents. The United States remains one of the most established commercial markets because of early adoption and a mature generic injectable ecosystem, while Europe combines stable institutional demand with stringent GMP and dossier requirements. Japan and other regulated Asian markets place strong emphasis on supplier consistency and change control. China is distinct because it combines a large fermentation-API manufacturing base with an expanding domestic generic-injectable market; inclusion of daptomycin injection in national volume-based procurement has increased the importance of API cost efficiency, forecast reliability and diversified qualified sourcing for finished-dose manufacturers.
Competition is led by a relatively small group of technically experienced anti-infective manufacturers in Europe and China, with regulatory reach and impurity-control capability serving as the primary differentiators. Xellia Pharmaceuticals manufactures the API in Budapest and supports U.S. and European regulatory dossiers, while ACS Dobfar supplies Daptomycin Drug Substance from its Italian anti-infective platform. In China, representative producers include Livzon Group Fuzhou Fuxing Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Medicine and the Huadong Medicine manufacturing system, alongside specialized suppliers such as Chongqing Daxin Pharmaceutical and Sichuan Novals Pharmaceuticals. Recent competitive activity is increasingly vertical rather than purely capacity-driven. Zhejiang Medicine’s controlled subsidiary Changhai Pharmaceutical obtained domestic approval for daptomycin API in 2023 after regulatory and FDA-related site work, and Zhejiang Medicine subsequently received Chinese approval for a 0.5 g daptomycin injectable in August 2024 after cumulative R&D spending of approximately RMB15.2 million on the formulation program. The move extends the company from drug-substance production into finished-dose commercialization. In parallel, Huadong Medicine’s manufacturing platform filed a 2024 patent covering high-purity daptomycin crystal preparation, emphasizing shorter purification, lower solvent consumption and industrial scalability, illustrating how process intensification is becoming a competitive asset.
Growth will be shaped by generic penetration, higher-purity API migration, second-source qualification and supply-chain resilience rather than unrestricted expansion in antibiotic consumption. On the demand side, persistent treatment needs for resistant Gram-positive infections support a stable clinical base, while antimicrobial stewardship and therapeutic alternatives such as vancomycin, linezolid and newer anti-MRSA agents cap volume elasticity. On the technology side, strain improvement, precision precursor feeding, online fermentation monitoring, selective chromatography, resin reuse and membrane-based concentration offer the clearest path to lower unit cost without compromising quality. Supply strategies are also changing: flexible multiproduct fermentation sites combined with dedicated critical purification steps and geographically diversified regulatory files are more attractive than large standalone daptomycin lines. Competitive advantage will increasingly reside with manufacturers able to support China, the United States, Europe and selected Asian markets from stable processes and harmonized dossiers. For Chinese suppliers, the most defensible opportunities are higher-purity grades, regulated-market second-source programs, domestic generic-injectable expansion and selective API-to-FDF integration; the principal constraints remain the narrow clinical scope, long customer-validation cycles, environmental-compliance costs, structural spare capacity and trade-policy uncertainty.
Report Scope
This report is a detailed and comprehensive analysis for global Daptomycin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Purity and by Finished-dose. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Daptomycin market size and forecasts, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Daptomycin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Daptomycin market size and forecasts, by Purity and by Finished-dose, in consumption value ($ Million), sales quantity (kg), and average selling prices (US$/kg), 2021-2032
Global Daptomycin market shares of main players, shipments in revenue ($ Million), sales quantity (kg), and ASP (US$/kg), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Daptomycin
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Daptomycin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Olon, Xellia Pharmaceuticals, Livzon Group Fuzhou Fuxing Pharmaceutical, Huadong Medicine, Zhejiang Hisun Pharmaceutical, Zhejiang Medicine, Chongqing Daxin Pharmaceutical, Lunan New Times Biotechnology, Sichuan Novals Pharmaceuticals, Fujian Comhony Biotechnology, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Daptomycin market is split by Purity and by Finished-dose. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Purity, and by Finished-dose in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market Segmentation
Market segment by Purity
≥99%
<99%
Market segment by Manufacturing Technology
Conventional Fed-batch
High-titer Optimized Fermentation
Market segment by Customer Business Model
Independent Generic Injectable Manufacturers
Vertically Integrated Pharmaceutical Groups
Others
Market segment by Finished-dose
500 mg/vial
350 mg/vial
Major players covered
Olon
Xellia Pharmaceuticals
Livzon Group Fuzhou Fuxing Pharmaceutical
Huadong Medicine
Zhejiang Hisun Pharmaceutical
Zhejiang Medicine
Chongqing Daxin Pharmaceutical
Lunan New Times Biotechnology
Sichuan Novals Pharmaceuticals
Fujian Comhony Biotechnology
Suzhou Biosynergy Pharmaceutical
North China Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter Outline
Chapter 1, to describe Daptomycin product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Daptomycin, with price, sales quantity, revenue, and global market share of Daptomycin from 2021 to 2026.
Chapter 3, the Daptomycin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Daptomycin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Purity and by Finished-dose, with sales market share and growth rate by Purity, by Finished-dose, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Daptomycin market forecast, by regions, by Purity, and by Finished-dose, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Daptomycin.
Chapter 14 and 15, to describe Daptomycin sales channel, distributors, customers, research findings and conclusion.